Treatment of ocular allergies: nonpharmacologic, pharmacologic and immunotherapy

References

• Williams H, Stewart A, von Mutius E, et al. Is eczema really on the increase worldwide? J Allergy Clin Immunol 2008;121(4):947-54
   PubMed Web of Science ®Google Scholar
• Asher MI, Montefort S, Björkstén B, et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 2006;368(9537):733-43
   PubMed Web of Science ®Google Scholar
• Bresciani M, Parisi C, Manghi G, et al. The hygiene hypothesis: does it function worldwide? Curr Opin Allergy Clin Immunol 2005;5(2):147-51
   PubMedGoogle Scholar
• Linneberg A, Nielsen NH, Madsen F, et al. Increasing prevalence of specific IgE to aeroallergens in an adult population: two cross-sectional surveys 8 years apart: the Copenhagen Allergy Study. J Allergy Clin Immunol 2000;106(2):247-52
   PubMed Web of Science ®Google Scholar
• D’amato G, Cecchi L, Bonini S, et al. Allergenic pollen and pollen allergy in Europe. Allergy 2007;62(9):976-90
   PubMed Web of Science ®Google Scholar
• Cabieses B, Uphoff E, Pinart M, et al. A systematic review on the development of asthma and allergic diseases in relation to international immigration: the leading role of the environment confirmed. PLoS One 2014;9(8):e105347
   PubMed Web of Science ®Google Scholar
• Gomes PJ. Trends in prevalence and treatment of ocular allergy. Curr Opin Allergy Clin Immunol 2014;14(5):451-6
   PubMed Web of Science ®Google Scholar
• Leonard A. Emerging drugs for ocular allergy. Expert Opin Emerg Drugs 2005;10(3):505-20
   PubMedGoogle Scholar
• Wolffsohn JS, Naroo SA, Gupta N, et al. Prevalence and impact of ocular allergy in the population attending UK optometric practice. Cont Lens Anterior Eye 2011;34(3):133-8
   PubMedGoogle Scholar
• Navarro A, Colas C, Anton E, et al. Epidemiology of allergic rhinitis in allergy consultations in Spain: Alergologica-2005. J Investig Allergol Clin Immunol 2009;19(Suppl 2):7-13
   PubMed Web of Science ®Google Scholar
• Schatz M. A survey of the burden of allergic rhinitis in the USA. Allergy 2007;62(Suppl 85):9-16
   PubMed Web of Science ®Google Scholar
• Bielory L. Ocular allergy overview. Immunol Allergy Clin North Am 2008;28(1):1-23
   PubMedGoogle Scholar
• Berdy GJ, Berdy SS. Ocular allergic disorders: disease entities and differential diagnoses. Curr Allergy Asthma Rep 2009;9(4):297-303
   PubMed Web of Science ®Google Scholar
• Chigbu DGI. The pathophysiology of ocular allergy: a review. Cont Lens Anterior Eye 2009;32(1):3-15
   PubMedGoogle Scholar
• Rosario N, Bielory L. Epidemiology of allergic conjunctivitis. Curr Opin Allergy Clin Immunol 2011;11(5):471-6
   PubMed Web of Science ®Google Scholar
• Chigbu DGI. The management of allergic eye diseases in primary eye care. Cont Lens Anterior Eye 2009;32(6):260-72
   PubMed Web of Science ®Google Scholar
• Kumar S. Vernal keratoconjunctivitis: a major review. Acta Ophthalmol 2009;87(2):133-47
   PubMed Web of Science ®Google Scholar
• Bonini S, Coassin M, Aronni S, et al. Vernal keratoconjunctivitis. Eye (Lond) 2004;18(4):345-51
   PubMed Web of Science ®Google Scholar
• Uchio E, Kimura R, Migita H, et al. Demographic aspects of allergic ocular diseases and evaluation of new criteria for clinical assessment of ocular allergy. Graefes Arch Clin Exp Ophthalmol 2008;246(2):291-6
   PubMedGoogle Scholar
• Bielory B, Bielory L. Atopic dermatitis and keratoconjunctivitis. Immunol Allergy Clin North Am 2010;30(3):323-36
   PubMed Web of Science ®Google Scholar
• Bonini S. Atopic keratoconjunctivitis. Allergy 2004;59(78):71-3
   PubMedGoogle Scholar
• Donshik PC, Ehlers WH, Ballow M. Giant papillary conjunctivitis. Immunol Allergy Clin North Am 2008;28(1):83-103
   PubMed Web of Science ®Google Scholar
• Bacon AS, Ahluwalia P, Irani AM, et al. Tear and conjunctival changes during the allergen-induced early-and late-phase responses. J Allergy Clin Immunol 2000;106(5):948-54
   PubMed Web of Science ®Google Scholar
• Choi SH, Bielory L. Late-phase reaction in ocular allergy. Curr Opin Allergy Clin Immunol 2008;8(5):438-44
   PubMedGoogle Scholar
• Ono SJ, Abelson MB. Allergic conjunctivitis: update on pathophysiology and prospects for future treatment. J Allergy Clin Immunol 2005;115(1):118-22
   PubMed Web of Science ®Google Scholar
• Leonardi A Motterle L, Bortolotti M. Allergy and the eye. Clin Exp Immunol 2008;153(1):17-21
   PubMedGoogle Scholar
• Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res 2002;21(3):319-39
   PubMedGoogle Scholar
• Tabbara KF. Ocular complications of vernal keratoconjunctivitis. Can J Ophthalmol 1999;34(2):88-92
   PubMed Web of Science ®Google Scholar
• Tuft SJ, Kemeny DM, Dart JK, et al. Clinical features of atopic keratoconjunctivitis. Ophthalmology 1991;98(2):150-8
   PubMedGoogle Scholar
• Donshik PC, Ehlers WH. Giant papillary conjunctivitis. Immunol Allergy Clin North Am 1997;17(1):53-73
   Google Scholar
• Bielory L. Ocular allergy treatment. Immunol Allergy Clin North Am 2008;8(1):189-224
   Google Scholar
• Friedlaender MH. Ocular allergy. Curr Opin Allergy Clin Immunol 2011;11(5):477-82
   PubMed Web of Science ®Google Scholar
• Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunol Allergy Clin North Am 2008;28(1):43-58
   PubMed Web of Science ®Google Scholar
• Asbell PA, Ahmad SM. Diagnostic assays in ocular allergy. Int Ophthalmol Clin 2003;43(1):83-93
   PubMedGoogle Scholar
• Veys J. Managing the contact lens wearing allergy sufferer. Optician 2004;5950(227):22-6
   Google Scholar
• Wolffsohn JS, Emberlin JC. Role of contact lenses in relieving ocular allergy. Cont Lens Anterior Eye 2011;4(4):169-72
   Google Scholar
• Gøtzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. Allergy 2008;63(6):646-59
   PubMed Web of Science ®Google Scholar
• Sheikh A, Hurwitz B, Nurmatov U, et al. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev 2010(7):CD001563
   Google Scholar
• Bush RK. Indoor allergens, environmental avoidance, and allergic respiratory disease. Allergy Asthma Proc 2008;29(6):575-9
   PubMedGoogle Scholar
• Wong AH, Barg SS, Leung AK. Seasonal and perennial allergic conjunctivitis. Recent Pat Inflamm Allergy Drug Discov 2009;3(2):118-27
   PubMedGoogle Scholar
• Bilkhu PS, Wolffsohn JS, Naroo SA, et al. Effectiveness of nonpharmacologic treatments for acute seasonal allergic conjunctivitis. Ophthalmology 2014;121(1):72-8
   PubMedGoogle Scholar
• Donshik PC. Contact lens chemistry and giant papillary conjunctivitis. Eye Contact Lens 2003;29(1):37-9
   Google Scholar
• Porazinski AD, Donshik PC. Giant papillary conjunctivitis in frequent replacement contact lens wearers: a retrospective study. Eye Contact Lens 1999;25(3):142-7
   Google Scholar
• Schultz BL. Pharmacology of ocular allergy. Curr Opin Allergy Clin Immunol 2006;6(5):383-9
   PubMedGoogle Scholar
• Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Curr Opin Allergy Clin Immunol 2005;5(5):437-40
   PubMed Web of Science ®Google Scholar
• Ciprandi G, Buscaglia S, Catrullo A, et al. Azelastine eye drops reduce and prevent allergic conjunctival reaction and exert anti-allergic activity. Clin Exp Allergy 1997;27(2):182-91
   PubMed Web of Science ®Google Scholar
• Giede-Tuch C, Westhoff M, Zarth A. Azelastine eye-drops in seasonal allergic conjunctivitis or rhinoconjunctivitis. Allergy 1998;53(9):857-62
   PubMed Web of Science ®Google Scholar
• Friedlaender MH, Harris J, LaVallee N, et al. Evaluation of the onset and duration of effect of azelastine eye drops (0.05%) versus placebo in patients with allergic conjunctivitis using an allergen challenge model. Ophthalmology 2000;107(12):2152-7
   PubMed Web of Science ®Google Scholar
• Netland PA, Leahy C, Krenzer KL. Emedastine ophthalmic solution 0.05% versus levocabastine ophthalmic suspension 0.05% in the treatment of allergic conjunctivitis using the conjunctival allergen challenge model. Am J Ophthalmol 2000;130(6):717-23
   PubMedGoogle Scholar
• Canonica GW, Ciprandi G, Petzold U, et al. Topical azelastine in perennial allergic conjunctivitis. Curr Med Res Opin 2003;19(4):321-9
   PubMed Web of Science ®Google Scholar
• Macejko TT, Bergmann MT, Williams JI, et al. Multicenter clinical evaluation of bepotastine besilate ophthalmic solutions 1.0% and 1.5% to treat allergic conjunctivitis. Am J Ophthalmol 2010;150(1):122-7
   PubMed Web of Science ®Google Scholar
• Williams JI, Kennedy KS, Gow JA, et al. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis. J Ocul Pharmacol Ther 2011;27(4):385-93
   PubMed Web of Science ®Google Scholar
• Meier EJ, Torkildsen GL, Gow JA, et al. Integrated phase III trials of bepotastine besilate ophthalmic solution 1.5% for ocular itching associated with allergic conjunctivitis. Allergy Asthma Proc 2012;33(3):265-74
   PubMed Web of Science ®Google Scholar
• Carr WW, Nayak AS, Ratner PH, et al. Efficacy of bepotastine besilate ophthalmic solution 1.5% for seasonal allergic conjunctivitis: a randomized, placebo-controlled, natural exposure, clinical trial. Allergy Asthma Proc 2013;34(3):247-54
   PubMed Web of Science ®Google Scholar
• Torkildsen GL, Williams JI, Gow JA, et al. Bepotastine besilate ophthalmic solution for the relief of nonocular symptoms provoked by conjunctival allergen challenge. Ann Allergy Asthma Immunol 2010;105(1):57-64
   PubMed Web of Science ®Google Scholar
• Bielory L, Lien KW, Bigelsen S. Efficacy and tolerability of newer antihistamines in the treatment of allergic conjunctivitis. Drugs 2005;65(2):215-28
   PubMed Web of Science ®Google Scholar
• Ousler GW, Workman DA, Torkildsen GL. An open-label, investigator-masked, crossover study of the ocular drying effects of two antihistamines, topical epinastine and systemic loratadine, in adult volunteers with seasonal allergic conjunctivitis. Clin Ther 2007;29(4):611-16
   PubMedGoogle Scholar
• Lanier BQ, Gross RD, Marks BB, et al. Olopatadine ophthalmic solution adjunctive to loratadine compared with loratadine alone in patients with active seasonal allergic conjunctivitis symptoms. Ann Allergy Asthma Immunol 2001;86(6):641-8
   PubMedGoogle Scholar
• Abelson MB, Kaplan AP. A randomized, double-blind, placebo-controlled comparison of emedastine 0.05% ophthalmic solution with loratadine 10 mg and their combination in the human conjunctival allergen challenge model. Clin Ther 2002;24(3):445-56
   PubMedGoogle Scholar
• Crampton HJ. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo-and active-controlled trial. Clin Ther 2003;25(7):1975-87
   PubMedGoogle Scholar
• Leino M, Ennevaara K, Latvala AL. Double-blind group comparative study of 2% nedocromil sodium eye drops with 2% sodium cromoglycate and placebo eye drops in the treatment of seasonal allergic conjunctivitis. Clin Exp Allergy 1992;22(10):929-32
   PubMedGoogle Scholar
• Blumenthal M, Casale T, Dockhorn R, et al. Efficacy and safety of nedocromil sodium ophthalmic solution in the treatment of seasonal allergic conjunctivitis. Am J Ophthalmol 1992;113(1):56-63
   PubMed Web of Science ®Google Scholar
• Cerqueti PM, Ricca V, Tosca MA, et al. Lodoxamide treatment of allergic conjunctivitis. Int Arch Allergy Immunol 1994;105(2):185-9
   PubMed Web of Science ®Google Scholar
• Abelson MB. Evaluation of olopatadine, a new ophthalmic antiallergic agent with dual activity, using the conjunctival allergen challenge model. Ann Allergy Asthma Immunol 1998;81(3):211-18
   PubMed Web of Science ®Google Scholar
• Kidd M, McKenzie SH, Steven I, et al. Efficacy and safety of ketotifen eye drops in the treatment of seasonal allergic conjunctivitis. Br J Ophthalmol 2003;87(10):1206-11
   PubMed Web of Science ®Google Scholar
• Abelson MB, Gomes P, Crampton HJ, et al. Efficacy and tolerability of ophthalmic epinastine assessed using the conjunctival antigen challenge model in patients with a history of allergic conjunctivitis. Clin Ther 2004;26(1):35-47
   PubMed Web of Science ®Google Scholar
• Avunduk AM, Tekelioglu Y, Turk A, et al. Comparison of the effects of ketotifen fumarate 0.025% and olopatadine HCl 0.1% ophthalmic solutions in seasonal allergic conjunctivitis: a 30-day, randomized, double-masked, artificial tear substitute-controlled trial. Clin Ther 2005;27(9):1392-402
   PubMedGoogle Scholar
• Tauber J, Raizman MB, Ostrov CS, et al. A multicenter comparison of the ocular efficacy and safety of diclofenac 0.1% solution with that of ketorolac 0.5% solution in patients with acute seasonal allergic conjunctivitis. J Ocul Pharmacol Ther 1998;14(2):137
   PubMedGoogle Scholar
• Swamy BN, Chilov M, McClellan K, et al. Topical non-steroidal anti-inflammatory drugs in allergic conjunctivitis: meta-analysis of randomized trial data. Ophthalmic Epidemiol 2007;14(5):311-19
   PubMed Web of Science ®Google Scholar
• Donshik PC, Pearlman D, Pinnas J, et al. Efficacy and safety of ketorolac tromethamine 0.5% and levocabastine 0.05%: a multicenter comparison in patients with seasonal allergic conjunctivitis. Adv Ther 2000;17(2):94-102
   PubMedGoogle Scholar
• Yaylali V, Demirlenk I, Tatlipinar S, et al. Comparative study of 0.1% olopatadine hydrochloride and 0.5% ketorolac tromethamine in the treatment of seasonal allergic conjunctivitis. Acta Ophthalmol Scand 2003;81:378-82
   PubMedGoogle Scholar
• Discepola M, Deschenes J, Abelson M. Comparison of the topical ocular antiallergic efficacy of emedastine 0.05% ophthalmic solution to ketorolac 0.5% ophthalmic solution in a clinical model of allergic conjunctivitis. Acta Ophthalmol Scand Suppl 1999;77(s228):43-6
   Google Scholar
• Sitenga GL, Ing EB, Van Dellen RG, et al. Asthma caused by topical application of ketorolac. Ophthalmology 1996;103(6):890-2
   PubMedGoogle Scholar
• Sharir M. Exacerbation of asthma by topical diclofenac. Arch Ophthalmol 1997;115(2):294-5
   PubMedGoogle Scholar
• Miyazaki D, Tominaga T, Kakimaru-Hasegawa A, et al. Therapeutic effects of tacrolimus ointment for refractory ocular surface inflammatory diseases. Ophthalmology 2008;115(6):988-92
   PubMed Web of Science ®Google Scholar
• Ebihara N, Ohashi Y, Uchio E, et al. A large prospective observational study of novel cyclosporine 0.1% aqueous ophthalmic solution in the treatment of severe allergic conjunctivitis. J Ocul Pharmacol Ther 2009;25(4):365-72
   PubMed Web of Science ®Google Scholar
• Bielory L, Mongia A. Current opinion of immunotherapy for ocular allergy. Curr Opin Allergy Clin Immunol 2002;2(5):447-52
   PubMedGoogle Scholar
• Dahl R, Kapp A, Colombo G, et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118(2):434-40
   PubMed Web of Science ®Google Scholar
• Durham SR, Walker SM, Varga EM, et al. Long-term clinical efficacy of grass-pollen immunotherapy. N Engl J Med 1999;341(7):468-75
   PubMed Web of Science ®Google Scholar
• Calderon MA, Penagos M, Sheikh A. Sublingual immunotherapy for allergic conjunctivitis: Cochrane systematic review and meta-analysis. Clin Exp Allergy 2011;41(9):1263-72
   PubMed Web of Science ®Google Scholar
• Erekosima N, Suarez-Cuervo C, Ramanathan M, et al. Effectiveness of subcutaneous immunotherapy for allergic rhinoconjunctivitis and asthma: a systematic review. Laryngoscope 2014;124:616-27
   PubMed Web of Science ®Google Scholar
• Tworek D, Bochenska-Marciniak M, Kuprys-Lipinska I, et al. Perennial is more effective than preseasonal subcutaneous immunotherapy in the treatment of seasonal allergic rhinoconjunctivitis. Am J Rhinol Allergy 2013;27:304-8
   PubMed Web of Science ®Google Scholar
• Klimek L, Schendzielorz P, Pinol R, et al. Specific subcutaneous immunotherapy with recombinant grass pollen allergens: first randomized dose-ranging safety study. Clin Exp Allergy 2012;42:936-45
   PubMed Web of Science ®Google Scholar
• Mahdy RAR, Nada WM, Marei AA. Subcutaneous allergen-specific immunotherapy versus topical treatment in vernal keratoconjunctivitis. Cornea 2012;31:525-8
   PubMed Web of Science ®Google Scholar
• Senti G, von Moos S, Tay F, et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen–induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012;129(1):128-35
   PubMed Web of Science ®Google Scholar
• Prete A, Loffredo C, Carderopoli A, et al. Local specific immunotherapy in allergic conjunctivitis. Acta Ophthalmol (Copenh) 1994;72(5):631-4
   PubMedGoogle Scholar
• Mortemousque B, Bertel F, De Casamayor J, et al. House-dust mite sublingual-swallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin Exp Allergy 2003;33(4):464-9
   PubMedGoogle Scholar
• Owen CG, Shah A, Henshaw K, et al. Topical treatments for seasonal allergic conjunctivitis: systematic review and meta-analysis of efficacy and effectiveness. Br J Gen Pract 2004;54(503):451-6
   PubMedGoogle Scholar
• Borazan M, Karalezli A, Akova YA, et al. Efficacy of olopatadine HCI 0.1%, ketotifen fumarate 0.025%, epinastine HCI 0.05%, emedastine 0.05% and fluorometholone acetate 0.1% ophthalmic solutions for seasonal allergic conjunctivitis: a placebo-controlled environmental trial. Acta Ophthalmol 2009;87(5):549-54
   PubMedGoogle Scholar
• Lanier BQ, Finegold I, D’Arienzo P, et al. Clinical efficacy of olopatadine vs epinastine ophthalmic solution in the conjunctival allergen challenge model. Curr Med Res Opin 2004;20(8):1227-33
   PubMed Web of Science ®Google Scholar
• Mah FS, Rosenwasser LJ, Townsend WD, et al. Efficacy and comfort of olopatadine 0.2% versus epinastine 0.05% ophthalmic solution for treating itching and redness induced by conjunctival allergen challenge. Curr Med Res Opin 2007;23(6):1445-52
   PubMed Web of Science ®Google Scholar
• Ousler GW, Gomes PJ, Welch D, et al. Methodologies for the study of ocular surface disease. Ocul Surf 2005;3(3):143-54
   PubMed Web of Science ®Google Scholar
• Greiner JV, Edwards-Swanson K, Ingerman A. Evaluation of alcaftadine 0.25% ophthalmic solution in acute allergic conjunctivitis at 15 minutes and 16 hours after instillation versus placebo and olopatadine 0.1%. Clin Ophthalmol 2011;5:87
   PubMedGoogle Scholar
• Torkildsen G, Shedden A. The safety and efficacy of alcaftadine 0.25% ophthalmic solution for the prevention of itching associated with allergic conjunctivitis. Curr Med Res Opin 2011;27(3):623-31
   PubMed Web of Science ®Google Scholar
• Ono SJ, Lane K. Comparison of effects of alcaftadine and olopatadine on conjunctival epithelium and eosinophil recruitment in a murine model of allergic conjunctivitis. Drug Des Devel Ther 2011;5:77
   PubMed Web of Science ®Google Scholar
• Ackerman S, D’Ambrosio Jr F, Greiner JV, et al. A multicenter evaluation of the efficacy and duration of action of alcaftadine 0.25% and olopatadine 0.2% in the conjunctival allergen challenge model. J Asthma Allergy 2013;6:43
   PubMedGoogle Scholar
• McCabe CF, McCabe SE. Comparative efficacy of bepotastine besilate 1.5% ophthalmic solution versus olopatadine hydrochloride 0.2% ophthalmic solution evaluated by patient preference. Clin Ophthalmol 2012;6:1731
   PubMedGoogle Scholar
• Mantelli F, Santos MS, Petitti T, et al. Systematic review and meta-analysis of randomised clinical trials on topical treatments for vernal keratoconjunctivitis. Br J Ophthalmol 2007;91(12):1656-61
   PubMed Web of Science ®Google Scholar
• Pucci N, Novembre E, Cianferoni A, et al. Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis. Ann Allergy Asthma Immunol 2002;89(3):298-303
   PubMed Web of Science ®Google Scholar
• Power WJ, Tugal-Tutkun I, Foster CS. Long-term follow-up of patients with atopic keratoconjunctivitis. Ophthalmology 1998;105(4):637-42
   PubMedGoogle Scholar
• Jackson BW. Blepharitis: current strategies for diagnosis and management. Can J Ophthalmol 2008;43(2):170-9
   PubMed Web of Science ®Google Scholar
• Lemp MA. Contact lenses and allergy. Curr Opin Allergy Clin Immunol 2008;8(5):457-60
   PubMedGoogle Scholar
• Daniell M, Constantinou M, Vu HT, et al. Randomised controlled trial of topical ciclosporin A in steroid dependent allergic conjunctivitis. Br J Ophthalmol 2006;90(4):461-4
   PubMed Web of Science ®Google Scholar
• Guglielmetti S, Dart JK, Calder V. Atopic keratoconjunctivitis and atopic dermatitis. Curr Opin Allergy Clin Immunol 2010;10(5):478-85
   PubMedGoogle Scholar
• Kruger CJ, Ehlers WH, Luistro AE, et al. Treatment of giant papillary conjunctivitis with cromolyn sodium. CLAO J 1992;18(1):46-8
   PubMedGoogle Scholar
• Lustine T, Bouchard CS, Cavanagh HD, et al. Continued contact lens wear in patients with giant papillary conjunctivitis. CLAO J 1991;17(2):104-7
   PubMedGoogle Scholar
• Khurana S, Sharma N, Agarwal T, et al. Comparison of olopatadine and fluorometholone in contact lens-induced papillary conjunctivitis. Eye Contact Lens 2010;36(4):210-14
   PubMedGoogle Scholar
• Hayes VY, Schnider CM, Veys J. An evaluation of 1-day disposable contact lens wear in a population of allergy sufferers. Cont Lens Anterior Eye 2003;26(2):85-93
   PubMedGoogle Scholar
• ElShaer A, Ghatora B, Mustafa S, et al. Contact lenses as drug reservoirs & delivery systems: the successes & challenges. Ther Deliv 2014;5(10):1085-100
   PubMedGoogle Scholar